摘要
目的:研究缬沙坦联合曲美他嗪治疗糖尿病心肌病(DCM)的临床效果。方法:选取2020年7月-2021年11月白银市中心医院收治的68例DCM患者为研究对象,将其随机分为对照组和研究组,各34例。对照组采用常规治疗,研究组采用缬沙坦联合曲美他嗪进行治疗,比较两组治疗效果。结果:治疗后1个月,两组左心室射血分数(LVEF)均高于治疗前,左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)均小于治疗前,血清肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)、血小板聚集率、反应指数均低于治疗前,且研究组均优于对照组(P<0.05)。研究组治疗过程中不良反应发生率低于对照组,治疗总有效率高于对照组(P<0.05)。结论:缬沙坦联合曲美他嗪能提高DCM患者的治疗效果,降低不良反应发生率和炎症因子水平,改善心功能和凝血异常情况。
Objective:To study the clinical effect of Valsartan combined with Trimetazidine in the treatment of diabetes cardiomyopathy(DCM).Method:A total of 68 patients with DCM who treated in Baiyin Central Hospital from July 2020 to November 2021 were selected as the research objects,and they were randomly divided into the control group and the study group,34 cases in each group.The control group was treated with routine treatment,and the study group was treated with Valsartan combined with Trimetazidine.The therapeutic effects of two groups were compared.Result:At 1 month after treatment,the left ventricular ejection fraction(LVEF)in two groups were higher than those before treatment,and the left ventricular end diastolic diameter(LVEDD)and left ventricular end systolic diameter(LVESD)were smaller than those before treatment,serum tumor necrosis factor-α(TNF-α),high-sensitivity C-reactive protein(hs-CRP),platelet aggregation rate and reaction index were lower than those before treatment,and the study group were better than those of the control group(P<0.05).The incidence of adverse reactions in the study group during treatment was lower than that in the control group,and the total effective rate was higher than that in the control group(P<0.05).Conclusion:Valsartan combined with Trimetazidine can improve the therapeutic effect of DCM patients,reduce the incidence of adverse reactions and the level of inflammatory factors,and improve the cardiac function and coagulation abnormalities.
作者
王鲜艳
WANG Xianyan(Baiyin Central Hospital,Baiyin 730913,China)
出处
《中外医学研究》
2023年第2期13-16,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
缬沙坦
曲美他嗪
糖尿病性心肌病
心功能
Valsartan
Trimetazidine
Diabetes cardiomyopathy
Cardiac function
